Locus Cell (TWSE: 6891), a leading regenerative medicine CDMO in Taiwan, has signed a Memorandum of Understanding (MOU) with Australia-based Cambium Bio (ASX: CMB) for the contract development and manufacturing of Elate Ocular®, a Phase III therapy for dry eye disease currently in clinical trials in Taiwan, the U.S., and Australia. The technology originates from Cambium’s parent company, Zheng Yang Biomedical Technology Co., Ltd.
Jiunn-Rong Chiou, Chairman of Locus Cell, said:
"This MOU represents our first Phase III international CDMO project and demonstrates the global capabilities of our Zhubei smart GMP facility. By integrating FDA-compliant electronic batch records, traceability, environmental monitoring, and data integrity, we are fully equipped to support global pharmaceutical partners."
In parallel, Cambium Bio recently signed a licensing MOU with France’s Benta SAS for Middle Eastern and European rights to Elate Ocular®. Outside of these regions, all international clinical and commercial manufacturing will be handled by Locus Cell, reinforcing its strategic role in the global supply chain.
Karolis Rosickas, CEO of Cambium Bio, added:
"Locus Cell’s Zhubei smart GMP facility meets FDA and GMP standards, offering digital-enabled flexibility and stability that will lower costs, ensure quality, and strengthen competitiveness. We look forward to expanding this partnership further."
This agreement marks a significant milestone for Locus Cell, highlighting its capabilities in global CDMO operations and commitment to supporting advanced regenerative medicine therapies worldwide.